drugset / Trial / NCT03209180
Immediate Release Versus Slow Release Carvedilol in Heart Failure
Phase 4
Unknown
320 enrolled
Seoul National University Bundang Hospital
Chong Kun Dang Pharmaceutical · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Assessment of clinical effect and treatment quality of immediate release carvedilol (IR) versus slow release carvedilol (SR) in patients with HFrEF
Timeline
- Start
- 2016-10-27
- Primary completion
- 2018-06-25
- Completion
- 2018-12-31
Publications
- Park CS, Park JJ, Lee HY, Kang SM, Yoo BS, Jeon ES, Hong SK, Shin JH, Kim MA, Park DG, Kim EJ, Hong SJ, Kim SY, Kim JJ, Choi DJ. Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study. Cardiovasc Drugs Ther. 2023 Jun;37(3):529-537. doi: 10.1007/s10557-021-07238-3. Epub 2022 Jan 23.
- Choi DJ, Park CS, Park JJ, Lee HY, Kang SM, Yoo BS, Jeon ES, Hong SK, Shin JH, Kim MA, Park DG, Kim EJ, Hong SJ, Kim SY, Kim JJ. Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial. Trials. 2018 Feb 13;19(1):103. doi: 10.1186/s13063-018-2470-5.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carvedilol | Other / unclassified | 3.125 mg | Oral |
| Subject | Carvedilol | Other / unclassified | 6.25 mg | Oral |
| Subject | Carvedilol | Other / unclassified | 8 mg | Oral |
| Subject | Carvedilol | Other / unclassified | 12.5 mg | Oral |
| Subject | Carvedilol | Other / unclassified | 16 mg | Oral |
| Subject | Carvedilol | Other / unclassified | 25 mg | Oral |
| Subject | Carvedilol | Other / unclassified | 32 mg | Oral |
| Subject | Carvedilol | Other / unclassified | 64 mg | Oral |